Please login to the form below

Not currently logged in
Email:
Password:

Prostrakan and Bayer Schering enter testosterone partnership

UK speciality pharmaceutical company ProStrakan has announced that it has granted Bayer Schering an exclusive license to develop and commercialise its testosterone gel

UK speciality pharmaceutical company ProStrakan has announced that it has granted Bayer Schering an exclusive license to develop and commercialise its testosterone gel, Tostran in 65 countries worldwide.

Tostran is a testosterone gel indicated for testosterone replacement therapy in men with hypogonadism, a condition where the testes fail to produce androgen and/or sperm.

Under the terms of the agreement, Bayer Schering will make an undisclosed upfront payment to ProStraken, which will be followed by milestone payments subject to certain approvals and sales targets being met.

Dr Wilson Totten, ProStrakan's chief executive, said: “Outlicensing Tostran to Bayer Schering Pharma in these territories is in line with our strategy of capitalising on the value of our products in parts of the world that are non-core for ProStrakan. In Bayer Schering Pharma, we have a worthy and sizeable partner with a deep understanding of the testosterone replacement market who is well-placed to bring this product to clinicians in each of these territories.”

Tostran is currently marketed in Europe under several brand names including Tostran, Tostrex and Itnogen. The product will be branded Fortigel in the US.

27th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics